Department of Pathology and Laboratory Medicine, Gustave Roussy Cancer Center, Villejuif, France.
INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif, France.
Int J Cancer. 2018 Jul 1;143(1):8-15. doi: 10.1002/ijc.31200. Epub 2017 Dec 23.
Over the last decade, increasing evidence highlights the role of the host immune system in the control of tumor growth and the prognostic implications of tumor infiltrating lymphocytes (TILs) in ovarian cancer. Most data support a better prognosis with accumulation of CD3+ and CD8 + TILs and a poor outcome associated with increased regulatory T cells. However, only a small number of studies have focused on the effect of neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment. This review will provide an update on the prognostic value of TIL subpopulations at diagnosis and a comprehensive overview of the recent studies evaluating the impact of neoadjuvant chemotherapy on TILs and their relationship to clinical outcome in advanced ovarian cancer. This information could help in future investigations of immunotherapy as maintenance following primary treatment.
在过去的十年中，越来越多的证据强调了宿主免疫系统在控制肿瘤生长和肿瘤浸润淋巴细胞（TILs）在卵巢癌中的预后意义。大多数数据支持 CD3+和 CD8+TIL 积累与更好的预后相关，而调节性 T 细胞增加与不良预后相关。然而，只有少数研究关注新辅助化疗（NACT）对肿瘤免疫微环境的影响。本综述将提供 TIL 亚群在诊断时的预后价值的最新信息，并全面概述最近评估新辅助化疗对 TIL 及其与晚期卵巢癌临床结局关系的研究。这些信息可能有助于未来对原发性治疗后维持免疫治疗的研究。
